Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

  • Home
  • Education
  • CIRTA 2017 - New York Recordings

2017 - CIRTA

This page contains exclusive content for the member of the following sections: TTS, ITA

Best Abstract Session

15.1 - Villin-1 is a novel serological biomarker for intestinal ischemia and reperfusion injury in rats and humans

Presenter: Laurens, Ceulemans, Leuven, Belgium
Authors: Laurens Ceulemans, Gert De Hertogh, Ricard Farré, Jean-Paul Decuypere, Len Verbeke, Ina Jochmans, Diethard Monbaliu, Kaatje Lenaerts, Jacques Pirenne

Villin-1 is a novel serological biomarker for intestinal ischemia and reperfusion injury in rats and humans

Laurens Ceulemans1, Gert De Hertogh2, Ricard Farré3, Jean-Paul Decuypere1, Len Verbeke3, Ina Jochmans1, Diethard Monbaliu1, Kaatje Lenaerts4, Jacques Pirenne1.

1Abdominal Transplant Surgery, University Hospitals Leuven, KULeuven, Leuven, Belgium; 2Pathology, University Hospitals Leuven, KULeuven, Leuven, Belgium; 3Gastro-enterology, University Hospitals Leuven, KULeuven, Leuven, Belgium; 4Surgery, University of Maastricht, Maastricht, Netherlands

Introduction: Intestinal ischemia remains a frequent pathology with a mortality rate up to 80%, due to delayed diagnosis and lack of efficient therapy. Intestinal reperfusion enhances the catastrophic effect of ischemia, known as ischemia-reperfusion injury (IRI). In contrast to other organs, serological markers for intestinal IRI are missing. We have accumulated evidence that villin-1 -a protein anchoring the actin filaments at the epithelial brush border- is a valuable candidate.

The aim was to analyze villin-1 as a serological biomarker in a rodent and human model of intestinal ischemia reperfusion injury (IRI).

Methods: In a rat model of intestinal IRI (temporary mesenteric artery clamping), 4 conditions were tested: (i) laparotomy only (sham); (ii) 30min ischemia + 5 reperfusion periods (0min/30min/60min/120min/24hours); (iii) 45min ischemia + 5 reperfusion periods; (iv) 60min ischemia + 5 reperfusion periods; (n=6/group). For survival analysis, 7-day reperfusion was included in each condition (n=10/group). Other end-points that were analyzed: histology (Park-Chiu/villus length); intestinal permeability (Ussing chamber); villin-1 (Western-Blot).

In a validated human model of intestinal IRI (6cm jejunal-clamping during pancreaticoduodenectomy; 45min ischemia + 0min/30min/120min reperfusion) villin-1 was analyzed by immunoprecipitation (n=6).

Results: In rat, increasing ischemia resulted in decreased survival (30min: 90%; 45min: 50%; 60min: 10%) and loss of intestinal integrity (histology/permeability). From 45min ischemia, villin-1 appeared in the plasma at 0min reperfusion and remained detectable until 120min reperfusion (Figure 1). At 0min reperfusion, villin-1 could differentiate between 45min or 60min ischemia corresponding to the different survival. Overall, villin-1 had a strong correlation with Park-Chiu score (r=0.7954;p<0.0001); villus length (r=-0.6585;p<0.0001); and permeability (r=-0.6127;p=0.0019).

In human, villin-1 was released with ischemia and remained detectable until 120min reperfusion (Figure 2).

Conclusion: For the first time, we showed that villin-1 is a serological biomarker of intestinal IRI in rat and human. These findings open new perspectives in the diagnosis of intestinal ischemia and warrant further clinical investigations.

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.